If, in the future, COL1A1 gene variants (particularly rs1800012) were included in a hypothetical panel of genetic markers for musculoskeletal disorders, it would be reasonable to inform TE patients—regardless of the type of planned therapy—about its potential limitations due to an increased risk of pain perception. Here, COL1A1 is linked to musculoskeletal system disorder.